Dimethyl fumarate shows efficacy in phase III clinical studies | Multiple Sclerosis Discovery Forum

The first peer-reviewed phase III clinical trials of an experimental oral drug for the most common form of multiple sclerosis met their expected benchmarks of efficacy and safety this week. The findings were widely previewed at meetings and in company press releases during the last year. Dimethyl fumarate (better known as BG-12, Biogen Idec) achieved key measures in two new studies with a combined population of about 2,600 people who have relapsing-remitting MS (RRMS).

No comments:

Post a Comment